-
Something wrong with this record ?
Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients
B. Mohelnikova-Duchonova, B. Melichar,
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Deoxycytidine analogs & derivatives therapeutic use MeSH
- Equilibrative Nucleoside Transporter 1 analysis genetics MeSH
- Humans MeSH
- Biomarkers, Tumor analysis genetics MeSH
- Pancreatic Neoplasms drug therapy metabolism MeSH
- Prognosis MeSH
- Antimetabolites, Antineoplastic therapeutic use MeSH
- Antineoplastic Agents therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Although systemic chemotherapy significantly improves the overall survival of pancreatic cancer patients, the prognosis remains extremely poor. The development of a drug resistance, either de novo or induced resistance, significantly limits the effectiveness of chemotherapy. SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. The aim of this mini-review is to summarize the current information concerning the prognostic and predictive role of SLC29A1 transporter (hENT1) expression in pancreatic cancer. Increased expression of SLC29A1 in vitro has been described as a potential critical factor determining the sensitivity of pancreatic cancer cells to gemcitabine and 5-fluorouracil, the principal cytotoxic agents used in the treatment of pancreatic cancer. The reports on the relationship between SLC29A1 expression and prognosis of patients with pancreatic cancer are currently rather conflicting. However, majority of studies on patients with resected pancreatic cancer have suggested that high SLC29A1expression may be predictive of improved survival in patients treated with gemcitabine. SLC29A1 has not been shown to represent a predictive biomarker for patients treated by 5-fluorouracil. In conclusion, potential prognostic and predictive role of SLC29A1 has been demonstrated for selected subset of patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14074469
- 003
- CZ-PrNML
- 005
- 20141009121851.0
- 007
- ta
- 008
- 141006s2013 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pan.2013.09.005 $2 doi
- 035 __
- $a (PubMed)24280569
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Mohelnikova-Duchonova, Beatrice $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; Biomedical Centre, Faculty of Medicine in Plzen, Charles University in Prague, Plzen, Czech Republic. Electronic address: beatrice.mohelnikova@gmail.com.
- 245 10
- $a Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients / $c B. Mohelnikova-Duchonova, B. Melichar,
- 520 9_
- $a Although systemic chemotherapy significantly improves the overall survival of pancreatic cancer patients, the prognosis remains extremely poor. The development of a drug resistance, either de novo or induced resistance, significantly limits the effectiveness of chemotherapy. SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. The aim of this mini-review is to summarize the current information concerning the prognostic and predictive role of SLC29A1 transporter (hENT1) expression in pancreatic cancer. Increased expression of SLC29A1 in vitro has been described as a potential critical factor determining the sensitivity of pancreatic cancer cells to gemcitabine and 5-fluorouracil, the principal cytotoxic agents used in the treatment of pancreatic cancer. The reports on the relationship between SLC29A1 expression and prognosis of patients with pancreatic cancer are currently rather conflicting. However, majority of studies on patients with resected pancreatic cancer have suggested that high SLC29A1expression may be predictive of improved survival in patients treated with gemcitabine. SLC29A1 has not been shown to represent a predictive biomarker for patients treated by 5-fluorouracil. In conclusion, potential prognostic and predictive role of SLC29A1 has been demonstrated for selected subset of patients.
- 650 _2
- $a protinádorové antimetabolity $x terapeutické užití $7 D000964
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a deoxycytidin $x analogy a deriváty $x terapeutické užití $7 D003841
- 650 _2
- $a ekvilibrační přenašeč nukleosidů 1 $x analýza $x genetika $7 D033721
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory slinivky břišní $x farmakoterapie $x metabolismus $7 D010190
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a nádorové biomarkery $x analýza $x genetika $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Melichar, Bohuslav
- 773 0_
- $w MED00008752 $t Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] $x 1424-3911 $g Roč. 13, č. 6 (2013), s. 558-63
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24280569 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20141006 $b ABA008
- 991 __
- $a 20141009122239 $b ABA008
- 999 __
- $a ok $b bmc $g 1042352 $s 873381
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 13 $c 6 $d 558-63 $i 1424-3911 $m Pancreatology $n Pancreatology $x MED00008752
- LZP __
- $a Pubmed-20141006
